SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Attributes and weights in health care priority setting: A systematic review of what counts and to what extent
13 references·1 citing·45 second hop
Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)Attributes and weights in health care pri…SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN (2012)SOCIETAL VIEWS ON NICE, CANCE…Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project (2010)Weighting and valuing quality…Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Using Effectiveness and Cost-…Severity of illness and priority setting in healthcare: A review of the literature (2009)Severity of illness and prior…The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 (2008)The Role of Value for Money i…QALY maximisation and people's preferences: a methodological review of the literature (2004)QALY maximisation and people'…Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Does NICE have a cost‐effecti…Resource allocation, social values and the QALY: a review of the debate and empirical evidence (2002)Resource allocation, social v…Preference for Equity As a Framing Effect (2001)Preference for Equity As a Fr…Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Health Economic Guidelines—Si…Helicopters, hearts and hips: Using willingness to pay to set priorities for public sector health care programmes (1998)Helicopters, hearts and hips:…Cost-Effectiveness Analysis in a Setting of Budget Constraints — Is It Equitable? (1996)Cost-Effectiveness Analysis i…Preferences for life saving programs: how the public discounts time and age (1994)Preferences for life saving p…Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review (2020)Examining Equity Effects of H…Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients (2001)Response Rates and Nonresponse Errors in Surveys (2012)Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries (2014)Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology (2014)Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature (2017)Judgment under Uncertainty: Heuristics and Biases (1974)Judgment under Uncertainty: Heuristics and Biases (1975)Methods for the Economic Evaluation of Health Care Programmes (2005)WTP for a QALY and health states: More money for severer health states? (2013)A new proposal for priority setting in Norway: Open and fair (2016)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? (2009)Intergenerational Equity: An Exploration of the ‘Fair Innings’ Argument (1997)Understanding DALYs (1997)Pricing and reimbursement of orphan drugs: the need for more transparency (2011)Multiple Criteria Decision Analysis for Health Technology Assessment (2012)Some empirical evidence on dynamic inconsistency (1981)Contingent weighting in judgment and choice. (1988)Statistical Efficiency of Double‐Bounded Dichotomous Choice Contingent Valuation (1991)A critical examination of summary measures of population health. (2000)INTEGRATING CELERITY, IMPULSIVITY, AND EXTRALEGAL SANCTION THREATS INTO A MODEL OF GENERAL DETERRENCE: THEORY AND EVIDENCE* (2001)Problems With the Interpretation of Pharmacoeconomic Analyses (2000)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part 2 - Implications for Interventional Pain Management (2010)Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (2015)Systematic overview of cost–effectiveness thresholds in ten countries across four continents (2015)Cost-Effectiveness in Health and Medicine (1996)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health (2005)Using Value of Information Analysis to Prioritise Health Research (2006)Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias (2009)Political Subjectivity: Applications of Q Methodology in Political Science (1982)Measurement of health state utilities for economic appraisal (1986)A Primer on Q Methodology (1993)The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions (2014)The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature (2014)Heuristics and biases in equity judgments: A utilitarian approach (1993)Chapter 2 An overview of the normative economics of the health sector (2000)Cost Effectiveness in Low- and Middle-Income Countries (2009)The Psychology of (In)Effective Altruism (2021)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group (2012)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)
this work references cited by second hop

References

  • 2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis710 cited
  • 2004QALY maximisation and people's preferences: a methodological review of the literature431 cited
  • 1994Preferences for life saving programs: how the public discounts time and age406 cited
  • 2009Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions343 cited
  • 2001Health Economic Guidelines—Similarities, Differences and Some Implications322 cited
  • 2010Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project276 cited
  • 1996Cost-Effectiveness Analysis in a Setting of Budget Constraints — Is It Equitable?225 cited
  • 2009Severity of illness and priority setting in healthcare: A review of the literature221 cited
  • 2008The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004217 cited
  • 2012SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN208 cited
  • 1998Helicopters, hearts and hips: Using willingness to pay to set priorities for public sector health care programmes194 cited
  • 2002Resource allocation, social values and the QALY: a review of the debate and empirical evidence183 cited
  • 2001Preference for Equity As a Framing Effect

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

71 cited

Cited by

  • 2020Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review84 cited